BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

123 related articles for article (PubMed ID: 1737799)

  • 1. Diverse biologic properties imparted by the c-fgr proto-oncogene.
    Sartor O; Moriuchi R; Sameshima JH; Severino M; Gutkind JS; Robbins KC
    J Biol Chem; 1992 Feb; 267(5):3460-5. PubMed ID: 1737799
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Comparison of src-family cDNAs reveals distinct mechanisms underlying focus formation in transfected fibroblasts.
    Sartor O; McLellan CA; Chiueh T
    J Biol Chem; 1992 Oct; 267(29):21044-51. PubMed ID: 1383216
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Translocation of the FGR protein-tyrosine kinase as a consequence of neutrophil activation.
    Gutkind JS; Robbins KC
    Proc Natl Acad Sci U S A; 1989 Nov; 86(22):8783-7. PubMed ID: 2682659
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The proto-oncogene c-fgr is expressed in normal mantle zone B lymphocytes and is developmentally regulated during myelomonocytic differentiation in vivo.
    Link DC; Zutter M
    Blood; 1995 Jan; 85(2):472-9. PubMed ID: 7812001
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Human c-fgr induces a monocyte-specific enzyme in NIH 3T3 cells.
    Inoue K; Wongsasant B; Akiyama T; Toyoshima K
    Mol Cell Biol; 1991 Dec; 11(12):6279-85. PubMed ID: 1944288
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Expression of the fgr protooncogene product as a function of myelomonocytic cell maturation.
    Notario V; Gutkind JS; Imaizumi M; Katamine S; Robbins KC
    J Cell Biol; 1989 Dec; 109(6 Pt 1):3129-36. PubMed ID: 2687293
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Cloning of the murine c-fgr proto-oncogene cDNA and induction of c-fgr expression by proliferation and activation factors in normal bone marrow-derived monocytic cells.
    Yi TL; Willman CL
    Oncogene; 1989 Sep; 4(9):1081-7. PubMed ID: 2674853
    [TBL] [Abstract][Full Text] [Related]  

  • 8. fgr proto-oncogene is expressed during terminal granulocytic differentiation of human promyelocytic HL60 cells.
    Miyazaki Y; Katamine S; Kohno T; Moriuchi R; Miyamoto T; Tomonaga M
    Exp Hematol; 1993 Feb; 21(2):366-71. PubMed ID: 8425574
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A novel c-fgr exon utilized in Epstein-Barr virus-infected B lymphocytes but not in normal monocytes.
    Gutkind JS; Link DC; Katamine S; Lacal P; Miki T; Ley TJ; Robbins KC
    Mol Cell Biol; 1991 Mar; 11(3):1500-7. PubMed ID: 1847500
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Primary structure of the human fgr proto-oncogene product p55c-fgr.
    Katamine S; Notario V; Rao CD; Miki T; Cheah MS; Tronick SR; Robbins KC
    Mol Cell Biol; 1988 Jan; 8(1):259-66. PubMed ID: 3275868
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The c-fgr proto-oncogene: expression in Epstein-Barr-virus-infected B lymphocytes and in cells of the myelomonocytic and granulocytic lineages.
    Patel M; Faulkner L; Katz DR; Brickell PM
    Pathobiology; 1991; 59(4):289-92. PubMed ID: 1652975
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Isolation and identification of two proto-oncogene products related to c-fgr and fyn in a tyrosine-protein-kinase fraction of rat spleen.
    Brunati AM; James P; Donella-Deana A; Matoskova B; Robbins KC; Pinna LA
    Eur J Biochem; 1993 Aug; 216(1):323-7. PubMed ID: 8365414
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Most of the substrates of oncogenic viral tyrosine protein kinases can be phosphorylated by cellular tyrosine protein kinases in normal cells.
    Kamps MP; Sefton BM
    Oncogene Res; 1988 Sep; 3(2):105-15. PubMed ID: 2465525
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Single point mutations in the SH2 domain impair the transforming potential of vav and fail to activate proto-vav.
    Katzav S
    Oncogene; 1993 Jul; 8(7):1757-63. PubMed ID: 8510922
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Structure of the complete human c-fgr proto-oncogene and identification of multiple transcriptional start sites.
    Patel M; Leevers SJ; Brickell PM
    Oncogene; 1990 Feb; 5(2):201-6. PubMed ID: 1690869
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Structural elements that regulate pp59c-fyn catalytic activity, transforming potential, and ability to associate with polyomavirus middle-T antigen.
    Cheng SH; Espino PC; Marshall J; Harvey R; Merrill J; Smith AE
    J Virol; 1991 Jan; 65(1):170-9. PubMed ID: 1985196
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A polymorphic microsatellite repeat is located close to the promoter region of the c-fgr proto-oncogene (FGR) at chromosome 1p36.2-p36.1.
    Patel MS; Mankoo BS; Brickell PM
    Hum Mol Genet; 1992 Apr; 1(1):65. PubMed ID: 1339476
    [No Abstract]   [Full Text] [Related]  

  • 18. Molecular cloning and sequencing of the murine c-fgr gene.
    King FJ; Cole MD
    Oncogene; 1990 Mar; 5(3):337-44. PubMed ID: 2179817
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The transforming potential of the c-erbB-2 protein is regulated by its autophosphorylation at the carboxyl-terminal domain.
    Akiyama T; Matsuda S; Namba Y; Saito T; Toyoshima K; Yamamoto T
    Mol Cell Biol; 1991 Feb; 11(2):833-42. PubMed ID: 1671296
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Regulation of c-Fgr protein kinase by c-Src kinase (CSK) and by polycationic effectors.
    Ruzzene M; James P; Brunati AM; Donella-Deana A; Pinna LA
    J Biol Chem; 1994 Jun; 269(22):15885-91. PubMed ID: 7515063
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.